Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Financial Results (Aug 5, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 5, 2025
Period End
August 5, 2025
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported second-quarter 2025 results for the period ended June 30, 2025, with total revenue of $325.7 milliona, up 41% year over year from $231.4 million.

Royalty revenue rose 65% to $205.6 millionb, driven mainly by DARZALEX SC, VYVGART Hytrulo and Phesgo. Net income was $165.2 million, compared with $93.2 million in the second quarter of 2024, and GAAP diluted EPS was $1.33, compared with $0.72. Adjusted EBITDA was $225.5 million, and Non-GAAP diluted EPS was $1.54.

The company raised its full-year 2025 guidance for the second time this year. Total revenue is now expected at $1,275 million to $1,355 millionc (previously $1,200 million to $1,280 million), royalty revenue at $825 million to $860 million (previously $750 million to $785 million), adjusted EBITDA at $865 million to $915 million (previously $790 million to $840 million), and Non-GAAP diluted EPS at $6.00 to $6.40 (previously $5.30 to $5.70). The guidance reflects tariffs currently in effect.

Capital allocation was active in the quarter. The company repurchased a total of $303.4 milliond of shares in the second quarter, including the $250 million program announced in May, and began a third $250 million tranche under its $750 million authorized program.

Cash, cash equivalents and marketable securities were $548.2 million at June 30, 2025. The filing also notes a patent infringement lawsuit filed in April 2025 against Merck Sharp & Dohme Corp. over its MDASE drug delivery technology, with $2.6 million of related litigation costs recognized in the quarter.

Key Highlights

  1. Total revenue of $325.7 million in Q2 2025, up 41% year over year, with royalties of $205.6 million, up 65%
  2. Net income of $165.2 million and GAAP diluted EPS of $1.33, versus $93.2 million and $0.72 in Q2 2024
  3. Full-year 2025 guidance raised: total revenue to $1,275-$1,355 million and adjusted EBITDA to $865-$915 million
  4. Non-GAAP diluted EPS guidance raised to $6.00-$6.40 from $5.30-$5.70, and royalty revenue guidance raised to $825-$860 million
  5. Share repurchases of $303.4 million in Q2 2025, with a third $250 million tranche initiated under the $750 million authorized program
  6. Cash, cash equivalents and marketable securities of $548.2 million at June 30, 2025, versus $596.1 million at December 31, 2024
  7. Patent infringement lawsuit against Merck Sharp & Dohme Corp. over MDASE SC drug delivery technology, with $2.6 million of litigation costs in the quarter

Frequently Asked Questions

  1. What drove the growth in second-quarter revenue?

    The 41% year-over-year increase in total revenue was primarily driven by royalty revenue growth and higher milestone revenues. Royalties rose 65% to $205.6 million, attributed mainly to increases in revenue from DARZALEX SC, VYVGART Hytrulo and Phesgo.

  2. How much did full-year 2025 guidance change?

    The company raised guidance for total revenue to $1,275-$1,355 million from $1,200-$1,280 million, royalty revenue to $825-$860 million from $750-$785 million, adjusted EBITDA to $865-$915 million from $790-$840 million, and Non-GAAP diluted EPS to $6.00-$6.40 from $5.30-$5.70. The EPS guidance does not consider potential future share repurchases.

  3. What share repurchase activity occurred in the quarter?

    The company completed a total of $303.4 million in share repurchases in the second quarter. This included a second $250 million tranche completed in June 2025 (4.8 million shares at an average price of $52.09) and the initiation of a third $250 million tranche under the $750 million program approved in February 2024, under which $53.5 million was used to buy about 1.0 million shares at an average of $52.40 in June.

  4. What is the status of the Merck litigation?

    In April 2025, Halozyme filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in the U.S. District Court in New Jersey, alleging that Merck is using Halozyme's patented MDASE SC drug delivery technology to develop SC Keytruda. Halozyme seeks damages and injunctive relief. The filing notes that there can be no assurance as to the litigation's developments, outcome or remedies.